Biopsy-based calibration of T2* magnetic resonance for estimation of liver iron concentration and comparison with R2 Ferriscan

BackgroundThere is a need to standardise non-invasive measurements of liver iron concentrations (LIC) so clear inferences can be drawn about body iron levels that are associated with hepatic and extra-hepatic complications of iron overload. Since the first demonstration of an inverse relationship between biopsy LIC and liver magnetic resonance (MR) using a proof-of-concept T2* sequence, MR technology has advanced dramatically with a shorter minimum echo-time, closer inter-echo spacing and constant repetition time. These important advances allow more accurate calculation of liver T2* especially in patients with high LIC.MethodsHere, we used an optimised liver T2* sequence calibrated against 50 liver biopsy samples on 25 patients with transfusional haemosiderosis using ordinary least squares linear regression, and assessed the method reproducibility in 96 scans over an LIC range up to 42 mg/g dry weight (dw) using Bland-Altman plots. Using mixed model linear regression we compared the new T2*-LIC with R2-LIC (Ferriscan) on 92 scans in 54 patients with transfusional haemosiderosis and examined method agreement using Bland-Altman approach.ResultsStrong linear correlation between ln(T2*) and ln(LIC) led to the calibration equation LIC = 31.94(T2*)-1.014. This yielded LIC values approximately 2.2 times higher than the proof-of-concept T2* method. Comparing this new T2*-LIC with the R2-LIC (Ferriscan) technique in 92 scans, we observed a close relationship between the two methods for values up to 10 mg/g dw, however the method agreement was poor.ConclusionsNew calibration of T2* against liver biopsy estimates LIC in a reproducible way, correcting the proof-of-concept calibration by 2.2 times. Due to poor agreement, both methods should be used separately to diagnose or rule out liver iron overload in patients with increased ferritin.

[1]  D. Pennell,et al.  Journal of Cardiovascular Magnetic Resonance Multi-center Transferability of a Breath-hold T2 Technique for Myocardial Iron Assessment , 2008 .

[2]  C. McLaren,et al.  Hepatic iron stores and plasma ferritin concentration in patients with sickle cell anemia and thalassemia major , 1993, American journal of hematology.

[3]  M. Kami,et al.  Hepatic iron concentration and total body iron stores in thalassemia major. , 2000, The New England journal of medicine.

[4]  S. Sheth,et al.  Noninvasive methods for quantitative assessment of transfusional iron overload in sickle cell disease. , 2001, Seminars in hematology.

[5]  Mark A Westwood,et al.  Interscanner reproducibility of cardiovascular magnetic resonance T2* measurements of tissue iron in thalassemia , 2003, Journal of magnetic resonance imaging : JMRI.

[6]  M. Cazzola,et al.  Relative response of patients with myelodysplastic syndromes and other transfusion-dependent anaemias to deferasirox (ICL670): a 1-yr prospective study , 2007, European journal of haematology.

[7]  N. Ghugre,et al.  Relaxivity‐iron calibration in hepatic iron overload: Probing underlying biophysical mechanisms using a Monte Carlo model , 2011, Magnetic resonance in medicine.

[8]  T. Coates,et al.  MRI R2 and R2* mapping accurately estimates hepatic iron concentration in transfusion-dependent thalassemia and sickle cell disease patients. , 2005, Blood.

[9]  Tim G St Pierre,et al.  Multicenter Validation of Spin-Density Projection-Assisted R2-MRI for the Noninvasive Measurement of Liver Iron Concentration , 2013, Magnetic resonance in medicine.

[10]  M. Cappellini,et al.  Tailoring iron chelation by iron intake and serum ferritin: the prospective EPIC study of deferasirox in 1744 patients with transfusion-dependent anemias , 2010, Haematologica.

[11]  S. Sherlock,et al.  Effect of ascorbic acid deficiency on serum ferritin concentration in patients with beta-thalassaemia major and iron overload. , 1982, Journal of clinical pathology.

[12]  A. Piga,et al.  Monitoring Long‐Term Efficacy of Iron Chelation Treatment with Biomagnetic Liver Susceptometry , 2005, Annals of the New York Academy of Sciences.

[13]  C. Gips,et al.  Measurement of iron in liver biopsies--a comparison of three analytical methods. , 1984, Clinica chimica acta; international journal of clinical chemistry.

[14]  C. Hillenbrand,et al.  R2* magnetic resonance imaging of the liver in patients with iron overload. , 2009, Blood.

[15]  J. D. Johnston Non-invasive assessment of hepatic iron stores by MRI. , 2004, Annals of clinical biochemistry.

[16]  D N Firmin,et al.  Cardiovascular T2-star (T2*) magnetic resonance for the early diagnosis of myocardial iron overload. , 2001, European heart journal.

[17]  G. Lucarelli,et al.  Needle liver biopsy in thalassaemia: analyses of diagnostic accuracy and safety in 1184 consecutive biopsies , 1995, British journal of haematology.

[18]  S. Perrotta,et al.  A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia. , 2006, Blood.

[19]  Mark Fogel,et al.  International reproducibility of single breathhold T2* MR for cardiac and liver iron assessment among five thalassemia centers , 2010, Journal of magnetic resonance imaging : JMRI.

[20]  M. Bronner,et al.  Quantitative study of the variability of hepatic iron concentrations. , 1999, Clinical chemistry.

[21]  M. de la Guardia,et al.  A comparative study of flame atomic-absorption methods for determination of zinc in serum and blood plasma. , 1984, Talanta.

[22]  T. S. St. Pierre,et al.  Noninvasive measurement and imaging of liver iron concentrations using proton magnetic resonance. , 2005, Blood.

[23]  Mark A Westwood,et al.  Multi-center validation of the transferability of the magnetic resonance T2* technique for the quantification of tissue iron. , 2006, Haematologica.

[24]  D. Pennell,et al.  Improved MRI R2* relaxometry of iron‐loaded liver with noise correction , 2013, Magnetic resonance in medicine.

[25]  S. Sherlock,et al.  Measurement of liver-iron concentration in needle-biopsy specimens. , 1971, Lancet.

[26]  C. Hillenbrand,et al.  Comparison of whole liver and small region-of-interest measurements of MRI liver R2* in children with iron overload , 2010, Pediatric Radiology.

[27]  R. Sposto,et al.  Ferritin trends do not predict changes in total body iron in patients with transfusional iron overload , 2014, American journal of hematology.

[28]  Roger Williams,et al.  Variability in hepatic iron concentration in percutaneous needle biopsy specimens from patients with transfusional hemosiderosis. , 2005, American journal of clinical pathology.

[29]  A. Taher,et al.  Efficacy and safety of deferasirox at low and high iron burdens: results from the EPIC magnetic resonance imaging substudy , 2012, Annals of Hematology.

[30]  J. Stessman,et al.  POTENTIAL PITFALL IN BIOASSAY OF SERUM-GENTAMICIN , 1975, The Lancet.

[31]  A. Zimmermann,et al.  A randomized controlled 1-year study of daily deferiprone plus twice weekly desferrioxamine compared with daily deferiprone monotherapy in patients with thalassemia major , 2007, Haematologica.

[32]  E. Huehns,et al.  Transfusion and exchange transfusion in sickle cell anaemias, with particular reference to iron metabolism. , 1987, Acta haematologica.

[33]  D. Altman,et al.  Measuring agreement in method comparison studies , 1999, Statistical methods in medical research.

[34]  T. Ganz,et al.  Liver iron concentrations and urinary hepcidin in beta-thalassemia. , 2007, Haematologica.

[35]  J. Ford,et al.  Semi-Quantitative Assessment of Hemosiderin Distribution Accurately Reflects Reductions in Liver Iron Concentration Following Therapy with Deferasirox (Exjade®, ICL670) or Deferoxamine in Patients with Transfusion-Dependent Anemia. , 2005 .

[36]  H. Eiskjaer,et al.  Evaluation of myocardial iron by magnetic resonance imaging during iron chelation therapy with deferrioxamine: indication of close relation between myocardial iron content and chelatable iron pool. , 2003, Blood.